Marco Herling

6.8k total citations
118 papers, 3.0k citations indexed

About

Marco Herling is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Marco Herling has authored 118 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pathology and Forensic Medicine, 53 papers in Oncology and 53 papers in Immunology. Recurrent topics in Marco Herling's work include Lymphoma Diagnosis and Treatment (50 papers), Chronic Lymphocytic Leukemia Research (48 papers) and CAR-T cell therapy research (24 papers). Marco Herling is often cited by papers focused on Lymphoma Diagnosis and Treatment (50 papers), Chronic Lymphocytic Leukemia Research (48 papers) and CAR-T cell therapy research (24 papers). Marco Herling collaborates with scholars based in Germany, United States and Italy. Marco Herling's co-authors include Dan Jones, L. Jeffrey Medeiros, Dan Jones, Michael Hallek, George Z. Rassidakis, Michael A. Teitell, Kaushali A. Patel, Michael J. Keating, Andreas H. Sarris and Madeleine Duvic and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marco Herling

110 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marco Herling Germany	29	1.2k	1.1k	1.1k	983	729	118	3.0k
Francisco J. Hernandez‐Ilizaliturri United States	30	2.0k 1.6×	925 0.8×	1.6k 1.5×	1.4k 1.4×	1.1k 1.4×	192	3.7k
M Stetler-Stevenson United States	22	677 0.6×	735 0.7×	869 0.8×	430 0.4×	680 0.9×	44	2.3k
Mamta Gupta United States	26	824 0.7×	524 0.5×	754 0.7×	569 0.6×	1.2k 1.7×	66	2.3k
Nilanjan Ghosh United States	28	939 0.8×	701 0.6×	1.4k 1.3×	424 0.4×	583 0.8×	160	2.4k
Yasuhito Terui Japan	31	817 0.7×	461 0.4×	1.0k 1.0×	591 0.6×	709 1.0×	126	2.4k
Justin L. Ricker United States	23	930 0.8×	558 0.5×	1.2k 1.1×	173 0.2×	2.5k 3.4×	63	4.0k
Patricia Pérez‐Galán Spain	27	839 0.7×	561 0.5×	867 0.8×	714 0.7×	1.7k 2.3×	68	2.9k
Mark N. Kirstein United States	21	1.0k 0.8×	362 0.3×	1.4k 1.3×	473 0.5×	1.4k 2.0×	56	3.4k
Pearlie K. Epling‐Burnette United States	34	718 0.6×	1.9k 1.7×	1.0k 0.9×	1.2k 1.2×	1.2k 1.6×	113	4.0k
Leslie A. Andritsos United States	30	1.5k 1.2×	1.1k 1.0×	1.0k 0.9×	2.1k 2.1×	967 1.3×	161	3.5k

Countries citing papers authored by Marco Herling

Since Specialization

Citations

This map shows the geographic impact of Marco Herling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Herling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Herling more than expected).

Fields of papers citing papers by Marco Herling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Herling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Herling. The network helps show where Marco Herling may publish in the future.

Co-authorship network of co-authors of Marco Herling

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Herling. A scholar is included among the top collaborators of Marco Herling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Herling. Marco Herling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marchi, Enrica, Tapan M. Kadia, Christina Poh, et al.. (2025). Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia. Blood. 146(Supplement 1). 777–777.

Angelucci, Emanuele, et al.. (2025). Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm. Leukemia & lymphoma. 66(13). 2489–2497.

Herling, Marco, Emanuele Angelucci, Antonio Curti, et al.. (2025). Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program. Annals of Hematology. 104(8). 4121–4131.

Schwind, Sebastian, Marius Bill, Juliane Grimm, et al.. (2024). Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?. HemaSphere. 8(3). e55–e55. 2 indexed citations

Herling, Marco, et al.. (2024). Real world (RW) study of patients (pts) with relapsed or refractory (RR) blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG).. Journal of Clinical Oncology. 42(16_suppl). e18533–e18533. 1 indexed citations

Herling, Marco, Claire Dearden, Francesco Zaja, et al.. (2024). Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Advances. 8(4). 842–845. 2 indexed citations

Glaß, Markus, Waseem Lone, Aleksandr Ianevski, et al.. (2023). The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL. Cancers. 15(9). 2527–2527. 5 indexed citations

Georgi, Thomas, Lars Kurch, Georg‐Nikolaus Franke, et al.. (2023). Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. Journal of Cancer Research and Clinical Oncology. 149(9). 6131–6138. 11 indexed citations

Jentzsch, Madlen, Klaus H. Metzeler, Maximilian Merz, et al.. (2022). Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer Journal. 12(12). 170–170. 20 indexed citations

10.

Herling, Marco, et al.. (2022). Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia. PLoS ONE. 17(9). e0274463–e0274463. 3 indexed citations

11.

Orlova, Anna, Johan Israelian, Peter Valent, et al.. (2022). JAK‐STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine. 26(7). 2049–2062. 62 indexed citations

12.

Nitzsche, Bianca, et al.. (2021). Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor. Pharmaceuticals. 14(12). 1319–1319. 6 indexed citations

13.

Biersack, Bernhard, et al.. (2021). Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors. International Journal of Molecular Sciences. 22(16). 8432–8432. 18 indexed citations

14.

Staber, Philipp B., Marco Herling, Mar Bellido, et al.. (2019). Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 134(14). 1132–1143. 67 indexed citations

15.

Crispatzu, Giuliano, Elena Vasyutina, Stefan Zittrich, et al.. (2016). A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells. Molecular Cancer Therapeutics. 15(5). 971–984. 8 indexed citations

16.

Holtick, Udo, Marco Herling, Natali Pflug, et al.. (2016). Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. Annals of Hematology. 96(3). 479–487. 18 indexed citations

17.

Schrader, Alexandra, Giuliano Crispatzu, Petra Mayer, et al.. (2014). AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1. Current Cancer Drug Targets. 14(8). 700–712. 3 indexed citations

18.

Prinz, Christian, Abdul Ali Peer‐Zada, Lalla A. Ba, et al.. (2011). Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic ‘sensor/effector’ compounds. Leukemia & lymphoma. 52(7). 1407–1411. 13 indexed citations

19.

Bouças, Jorge, et al.. (2010). Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia. Leukemia & lymphoma. 51(8). 1375–1378. 4 indexed citations

20.

Hoyer, Katrina K., Marco Herling, Ksenia Bagrintseva, et al.. (2005). T Cell Leukemia-1 Modulates TCR Signal Strength and IFN-γ Levels through Phosphatidylinositol 3-Kinase and Protein Kinase C Pathway Activation. The Journal of Immunology. 175(2). 864–873. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact